Why is "Encorafenib" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-08-06 16:35:45
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Encorafenib entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-08-06 and was most recently seen on 2026-08-06.
Wikipedia Overview
Encorafenib, sold under the brand name Braftovi, is an anti-cancer medication used for the treatment of certain melanoma cancers. It is a small molecule BRAF inhibitor that targets key enzymes in the MAPK signaling pathway. This pathway occurs in many different cancers including melanoma and colorectal cancers.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
EC Approves Encorafenib/Cetuximab/FOLFOX in 1L BRAF V600E–Mutant mCRC - CancerNetwork
-
FDA Approves Encorafenib (Braftovi) Combination for Metastatic Colorectal Cancer - Oncology News Central
-
BREAKWATER Cohort 3 Data Support FOLFIRI as Chemotherapy Backbone With Encorafenib/Cetuximab in BRAF V600E+ mCRC - OncLive
-
BREAKWATER Update: Encorafenib + Cetuximab + FOLFIRI Improves PFS, Lengthens OS in BRAF - dailynews.ascopubs.org
-
Adding Encorafenib and Cetuximab to FOLFIRI Shows Benefit in BRAF-Mutant Colorectal Cancer - The ASCO Post
-
Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial - Nature
-
BREAKWATER Supports FDA Approval of Encorafenib-Cetuximab-FOLFIRI for BRAF V600E-Mutant mCRC - Cancer Therapy Advisor
-
Laboratoires Pierre Fabre receives European Commission Approval for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metast - PR Newswire
-
Encorafenib and Cetuximab Plus FOLFIRI Improves Outcomes in BRAF V600E-Mutant Metastatic Colorectal Cancer - HMP Global Learning Network
-
Encorafenib Combo Boosts PFS in BRAF V600E+ Metastatic Colorectal Cancer - Targeted Oncology
-
FDA Approves Encorafenib Combination in BRAF V600E+ mCRC - Oncology Nursing News
-
FDA Grants Traditional Approval to Encorafenib Combination for Metastatic CRC With BRAF V600E Mutation - The American Journal of Managed Care
-
FDA Grants Full Approval to Encorafenib Plus Cetuximab/Chemotherapy for BRAF V600E+ mCRC - OncLive
-
Cost-effectiveness analysis of encorafenib in untreated BRAF V600E -mutant metastatic colorectal cancer in China - Nature
-
BRAF V600E–Mutant Colorectal Cancer: First-Line Encorafenib, Cetuximab, and FOLFIRI - The ASCO Post
-
FDA Grants Encorafenib Combo Traditional Approval in BRAF V600E+ mCRC - Targeted Oncology
-
CHMP Backs Encorafenib Plus Cetuximab and FOLFOX as First-Line Option for BRAF V600E–Mutant mCRC - OncLive
-
FDA Approves Encorafenib for Metastatic BRAF V600E–Mutated Colorectal Cancer - The ASCO Post
-
Encorafenib/Cetuximab Plus FOLFIRI Prolongs PFS Over SOC in BRAF V600E–Mutant mCRC - OncLive
-
Dr Pant on the FDA Approval of First-Line Encorafenib Plus Cetuximab/Chemo in BRAF V600E–Mutant mCRC - OncLive
-
Encorafenib/Cetuximab Plus FOLFIRI Represents Potential New Frontline SOC in BRAF V600E+ mCRC - OncLive
-
FDA OKs Guardant360 CDx for Encorafenib Combo in BRAF V600E+ Metastatic CRC - Targeted Oncology
-
Management of Metastatic Colorectal Cancer With a BRAF V600E Mutation - Cancer Therapy Advisor
-
BREAKWATER at ASCO 2026: Encorafenib plus Cetuximab and FOLFIRI in BRAF V600E-Mutant mCRC - Oncodaily
-
Targeted Combo Boosts PFS in BRAF-Mutant Metastatic Colorectal Cancer - MedPage Today
-
FDA Approves Guardant360 as Encorafenib Companion Diagnostic in BRAF V600E–Mutant mCRC - OncLive
-
FDA Grants Traditional Approval to Encorafenib (Braftovi) for BRAF V600E–Mutant Metastatic Colorectal Cancer - Consultant360
-
Eruptive Verrucous Keratoses and Melanocytic Nevi Induced by Encorafenib Plus Cetuximab in a Patient With Metastatic Colorectal Cancer - ScienceDirect.com
-
CHMP Recommends BREAKWATER Regimen for Approval in 1L BRAF V600E+ mCRC - CancerNetwork
-
FDA Approves Liquid Biopsy CDx for Encorafenib Regimen in BRAF V600E+ CRC - CancerNetwork
-
FDA Approves Encorafenib Combination for BRAF V600E–Mutated Metastatic Colorectal Cancer - Pharmacy Times
-
Encorafenib Plus Cetuximab, FOLFIRI Demonstrates Significant PFS Benefit in BRAF V600E-Mutant Metastatic Colorectal Cancer - Pharmacy Times
-
FOLFIRI Emerges as a New Backbone in BRAF V600E–Mutant Metastatic Colorectal Cancer - HMP Global Learning Network
-
Encorafenib–Cetuximab–Nivolumab in MSS BRAF mCRC - Oncodaily
-
EC approves Erbitux combination for first‑line treatment of BRAF V600E‑mutant mCRC - PharmaTimes
-
Expansion of Targeted Therapies Into Earlier Lines Reinforces Need for Upfront Biomarker Testing in mCRC - OncLive
-
Results of the Breakwater Trial Shows Encorafenib to Improve Progression-Free Survival in Metastatic Colorectal Cancer - Onco'Zine
-
Analysis from the AGEO group: Switching Cetuximab to Panitumumab During Encorafenib Therapy in BRAF V600E–Mutated mCRC - Oncodaily
-
Targeted Duo Wins Again in BRAF-Mutant Colorectal Cancer - MedPage Today
-
Braftovi Combo Improves Response in BRAF V600E Metastatic Colorectal Cancer - Cure Today
-
Pierre Fabre wins EC approval for Braftovi regimen in BRAFV600E‑mutant mCRC - PharmaTimes
-
A New First-Line Option in BRAF -Mutant Metastatic CRC? - Medscape
-
Potential new first-line treatment strategy for patients with BRAF V600E-mutant metastatic colorectal cancer - VHIO
-
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial - Nature
-
BRAF V600E metastatic colorectal cancer: encorafenib plus cetuximab plus mFOLFOX6 moves to first line under accelerated approval - Vera Health
-
3 PATHOPHYSIOLOGY OF CARDIOTOXICITY WITH BRAF/MEK INHIBITORS - bpspubs.onlinelibrary.wiley.com
-
Targeted Strategies, Systemic Therapies, and AI Advances Emerge as Central Themes From ASCO GI 2026 - OncLive
-
U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer - Business Wire
-
Encorafenib/Cetuximab Plus FOLFIRI Shows Promise in mCRC - Targeted Oncology
-
Triple Combination of Encorafenib, Cetuximab, and Nivolumab in MSS BRAFV600E Metastatic Colorectal Cancer - Oncodaily
-
FDA Approves Companion Diagnostic for Colorectal Cancer Treatment - Clinical Lab Products
-
Second-generation BRAF inhibitor Encorafenib resistance is regulated by NCOA4-mediated iron trafficking in the drug-resistant malignant melanoma cells | Scientific Reports - Nature
-
Bilateral exudative retinal detachment in the macula a few hours after oral administration of melanoma drugs — binimetinib and encorafenib: a case report | Grzegórzko | Ophthalmology Journal - journals.viamedica.pl
-
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer - NEJM
-
Pfizer’s Braftovi combination therapy shows positive results for colorectal cancer - PMLiVE
-
Encorafenib-Cetuximab Plus Chemotherapy Improves Survival in BRAF V600E-Mutant Metastatic Colorectal Cancer - The ASCO Post
-
Adjuvant Encorafenib/Binimetinib Is Well Tolerated and May Reduce Recurrence Risk in BRAF V600–Mutant Melanoma - OncLive
-
Encorafenib Combo Earns Chinese Approval in BRAF V600E+ Metastatic CRC - CancerNetwork
-
Subgroup Analysis Supports Encorafenib Plus Cetuximab/mFOLFOX6 as New SOC for BRAF V600E+ mCRC - OncLive
-
Encorafenib Triplet Could Address Poor Outcomes With Immunotherapy in BRAF V600–Mutant Melanoma With Brain Metastases - OncLive
-
Encorafenib Combo Earns European Approval in Advanced BRAF+ NSCLC - CancerNetwork
-
Encorafenib/Binimetinib Induction Before Nivolumab/Ipilimumab Does Not Boost PFS in BRAF V600E/K+ Metastatic Melanoma - OncLive
-
Encorafenib/Binimetinib/Nivolumab Improves PFS in BRAF V600+ Melanoma with Symptomatic Brain Metastases - OncLive
-
Encorafenib Triplet Exhibits Early Efficacy in MSS BRAFV600E Metastatic CRC - CancerNetwork
-
Encorafenib/Cetuximab Plus Chemo Improves Survival in BRAF V600E+ mCRC - OncLive
-
Positive new data on Pfizer’s Braftovi regimen - The Pharma Letter
-
Dr Eroglu on Safety Considerations for Encorafenib/Binimetinib/Nivolumab in BRAF V600+ Melanoma - OncLive
-
FDA grants full approval to Pfizer’s Braftovi combo - The Pharma Letter
-
FDA Approves Encorafenib/Binimetinib for BRAF V600E+ NSCLC - Oncology Nursing News
-
FDA Approves Encorafenib With Binimetinib for Metastatic BRAF V600E–Mutated NSCLC - The ASCO Post
-
Dr Murray on the Safety of Encorafenib/Binimetinib and Dabrafenib/Trametinib in BRAF V600E+ NSCLC - OncLive
-
Encorafenib + Binimetinib Displays Promising Safety, Efficacy Signals in BRAFV600E/K–Mutated Melanoma - dailynews.ascopubs.org
-
Dr Chiorean on Encorafenib Plus Cetuximab for BRAF V600E–Mutated mCRC - OncLive
-
Novel CDK2/CDK9 inhibitor fadraciclib targets cell survival and DNA damage pathways and synergizes with encorafenib in human colorectal cancer cells with BRAF(V600E) - Nature
-
Braftovi (Encorafenib) Combination FDA Approved for First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer - news.cancerconnect.com
-
Encorafenib Plus Cetuximab and mFOLFOX6 for Patients With BRAF V600E-Mutated Metastatic Colorectal Cancer - HMP Global Learning Network
-
Encorafenib, Cetuximab Combination Approved for Metastatic Colorectal Cancer - National Cancer Institute (.gov)
-
FDA Grants Accelerated Approval to Encorafenib/Cetuximab/Chemo Combo in BRAF V600E+ mCRC - Targeted Oncology
-
Encorafenib/Binimetinib Induction Improves PFS in Some Patients With Advanced BRAFV600E/K–Mutant Melanoma - dailynews.ascopubs.org
-
FDA Greenlights Encorafenib/Binimetinib for BRAF V600E-Mutated NSCLC - Targeted Oncology
-
Triplet Regimen Demonstrates Benefit in BRAF V600E–Mutant Metastatic Colorectal Cancer - The ASCO Post
-
Encorafenib/Cetuximab Plus Chemo Drives ORR Improvement in BRAF V600E+ mCRC - OncLive
-
Fore Bio’s plixorafenib receives FDA Breakthrough Therapy status for BRAF-mutated glioma - allsci.com
-
FDA Greenlights Companion Diagnostic for Encorafenib Plus Cetuximab in BRAF V600E+ mCRC - OncLive
-
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC) - OncLive
-
FDA Grants Accelerated Approval to Encorafenib (Braftovi) Combination for Metastatic Colorectal Cancer - Oncology News Central
-
Sequencing of Ipilimumab/Nivolumab With Encorafenib/Binimetinib in BRAF-Mutant Metastatic Melanoma - The ASCO Post
-
First-line Combination Therapy for BRAF-mutated Metastatic Colorectal Cancer - American Association for Cancer Research (AACR)
-
Melanoma New Data on Encorafenib, Binimetinib, Ipilimumab, and Nivolumab - The ASCO Post
-
Encorafenib/Cetuximab/Binimetinib Triplet Safe and Effective in BRAF V600E–Mutant mCRC - Oncology Nursing News
-
A plain language summary of the COLUMBUS study: encorafenib plus binimetinib for BRAF V600-mutant melanoma - Oncology Central
-
BREAKWATER: Encorafenib, Cetuximab, & mFOLFOX6 Advance mCRC Care - Targeted Oncology
-
Updated Results Confirm Benefit of Combination Regimen in BRAFV600E–Mutated Metastatic Colorectal Cancer - The ASCO Post
-
Adding Nivolumab to Encorafenib/Cetuximab Yields High Response Rates in MSS, BRAF V600E+ CRC - Oncology Nursing News
-
FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer - OncLive
-
Encorafenib Plus Binimetinib for BRAF-Mutated Metastatic Melanoma: 7-Year Follow-Up Data From the COLUMBUS Trial - OncLive
-
FDA Approves Encorafenib Plus Binimetinib for Non-Small Cell Lung Cancer - Oncology News Central
-
FDA Approves Encorafenib and Binimetinib - The ASCO Post
-
Dr Imanirad on Toxicity Management for Encorafenib Plus Cetuximab in BRAF-Mutant mCRC - OncLive
-
MEK and BRAF Inhibitors and the Risk of Ocular Toxicity - Ophthalmology Advisor
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.